ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 3031 • 2016 ACR/ARHP Annual Meeting

    Rethinking Primary Sjögren’s Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains?

    Dennis Lendrem1, Nadia Howard Tripp2,3, Xavier Mariette4, Svein Joar A. Johnsen5, Jessica Tarn6, Katie Hackett6, Bridget Griffiths7, Sheryl Mitchell8, Alain Saraux9, Valerie Devauchelle10, Katrine Norheim11, John D. Isaacs12, Peter McMeekin13,14, Simon Bowman15, Roald Omdal16, Jacques-Eric Gottenberg17 and Wan-Fai Ng18, 1Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, United Kingdom, 2Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 3Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom, 4Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 5Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 6Newcastle University, Newcastle-upon-Tyne, United Kingdom, 7Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 8Freeman Hospital, Newcastle upon Tyne, United Kingdom, 9Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, 10Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, 11Stavanger University Hospital, Stavanger, Norway, 12Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom, 13Institute of Health and Society, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 14Northumbria University, Newcastle-upon-Tyne, United Kingdom, 15Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 16University of Bergen, Bergen, Norway, 17Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 18Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Primary SjšgrenÕs Syndrome (pSS) is a chronic autoimmune rheumatic disease causing a wide-range of symptoms including dryness, pain and fatigue. Individual patient experiences of…
  • Abstract Number: 25 • 2016 ACR/ARHP Annual Meeting

    Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4

    James Gwinnutt1, Deborah P.M. Symmons1,2, Alex J Macgregor3,4, Jacqueline Chipping3,4, Tarnya Marshall3,4, Mark Lunt1 and Suzanne M.M. Verstappen1, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 3Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, 4School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom

    Background/Purpose: New treatments have improved the short term outlook for patients with inflammatory polyarthritis (IP) over the past 20 years. However there is limited evidence…
  • Abstract Number: 511 • 2016 ACR/ARHP Annual Meeting

    Complement C3 and C4 Levels and Its Correlation with Disease Activity in Rheumatoid Arthritis Patients

    Julia Sosa1, Silvia Beatriz Papasidero2, María Alejandra Medina1, Diana Klajn3, Rafael Chaparro del Moral2, José Angel Caracciolo4, Luciana Casalla5, Lucía Zárate5, Nieves Capozzi5, Josefina Marcos6, Mercedes Argentina García6, Ana Quinteros7, Maria Olga Leal7, Dora Lia Vásquez7, María Inés Stancich8, Analia Alvarez9, Carolina Sanchez Andía9, Karin Kirmayr10, María de los Ángeles Correa11 and A. Constantino12, 1Rheumatology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 2Rheumatology Department, Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 3Research Committee, Research Committee, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 4Rhematology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 5Rheumatology Section, Hospital Posadas, Buenos Aires, Argentina, 6Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, 7Centro Integral De Reumatologia, Tucumán, Argentina, 8Rheumatology Department, Hospital Nacional De Clínicas, Córdoba, Argentina, 9Rheumatology Department, Hospital Penna, Buenos Aires, Argentina, 10Rheumatology Department, Sanatorio San Carlos, Buenos Aires, Argentina, 11Rheumatology Department, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 12Hospital Nacional De Clínicas, Córdoba, Argentina

    COMPLEMENT C3 AND C4 LEVELS AND ITS CORRELATION WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS   Background/Purpose: Cytokines play a major role in the pathogenesis…
  • Abstract Number: 754 • 2016 ACR/ARHP Annual Meeting

    The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus

    Rattapol Pakchotanon1, Dafna D. Gladman2, Jiandong Su2 and Murray Urowitz3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…
  • Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting

    Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform

    Chaim Putterman1, Pennina Safer2, Keren Jakobi2, Rachel Sorek2, Ilana Gilkaite2, Kyle Ferber3, Steve Wallace3, Amanda Harris Altice3, D. Scott Batty3 and Irun R Cohen2,4, 1Albert Einstein College of Medicine, Bronx, NY, 2ImmunArray LTD, Rehovot, Israel, 3ImmunArray Inc., Richmond, VA, 4Immunology, Weizmann Institute of Science, Rehovot, Israel

    Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
  • Abstract Number: 1471 • 2016 ACR/ARHP Annual Meeting

    Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake in RA Patients without Clinical Cardiovascular Disease Is Higher Than in Controls and Decreases with Treatment

    Isabelle Amigues1, Jon T. Giles2, Afshin Zartoshti3, Rachelle Morgenstern4, Raul Flores5, Sabahat Bokhari6 and Joan Bathon7, 1Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 2Rheumatology, Columbia University Medical Center, NY, NY, 3Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, 4Cardiology, columbia university college of physicians and surgeons, New York city, NY, 5Medicine, Columbia University, New York Presbyterian, New York city, NY, 6Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, 7Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY

    Background/Purpose:   Symptomatic heart failure (HF) and HF-associated mortality rates are higher in RA compared with the non-RA population, even after controlling for coronary artery…
  • Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting

    The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis

    Agnes Szentpetery1, Natsumi Ikumi1, Brian Kirby2 and Oliver FitzGerald3, 1St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, 2St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland, 3St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

    Background/Purpose:   Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…
  • Abstract Number: 2082 • 2016 ACR/ARHP Annual Meeting

    Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)

    Jianlin Huang1, Hongzhi Wang2, Jing Yang3, Wenqiang Fan4, Hua Wei5, Rong Mu6, Xinwang Duan7, Xiangyuan Liu8, Fang He9, Zhenchun Zhang10, Fei Xiao11, Hui Xiao11, Yuhua Jia11, Yuan Liu11, Li Zhang11, Bing Wu11 and Xiaofeng Li12, 1Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, 2The First Hospital of Jiaxing, Jiaxing, China, 3Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, 4Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, 5No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, 6Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 7Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, 8Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, 9Central Hospital of Sui Ning, Sichuan, Suining, China, 10People's Hospital of Linyi, Shandong, Linyi, China, 11Gothic Internet Technology Corporation, Shanghai, China, 12The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China

    Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-target (T2T) is a widely accepted cretria as…
  • Abstract Number: 2518 • 2016 ACR/ARHP Annual Meeting

    Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time

    Nicola J Gullick1, Fowzia Ibrahim2, Aneela Mian1, Alexandra Vincent3, Gabriel Panayi1, Brian Tom4, David L. Scott1 and Bruce Kirkham3, 1Rheumatology, King's College London, London, United Kingdom, 2Academic Rheumatology Dept, King's College London, London, United Kingdom, 3Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, 4Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom

    Background/Purpose: There has been increasing emphasis on intensive treatment of RA but little direct evidence of the impact of such strategies on long term outcome.…
  • Abstract Number: 2780 • 2016 ACR/ARHP Annual Meeting

    A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life

    Matthew Got1, Suzanne Li2, Anthony V. Perruccio3,4, Dafna D Gladman1 and Vinod Chandran5, 1University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 4Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 5Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a…
  • Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting

    Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA

    Susan J. Bartlett1,2, Orit Schieir3, Kathleen Andersen4, Gilles Boire5, Boulos Haraoui6, Carol Hitchon7, Edward Keystone8, Janet E. Pope9, J Carter Thorne10, Diane Tin11, Vivian P. Bykerk12 and Canadian Early Arthritis Cohort (CATCH) Investigators, 1Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Toronto, Toronto, ON, Canada, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 61551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 9University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 12Divison of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
  • Abstract Number: 31 • 2016 ACR/ARHP Annual Meeting

    Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)

    Charlotte Jacquemin1, Herve Servy2, Anna Molto3, Jeremie Sellam4, Violaine Foltz1, Frédérique Gandjbakhch1, Christophe Hudry3, Stéphane Mitrovic1, Bruno Fautrel1 and Laure Gossec1, 1Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 2Sanoia, La Ciotat, France, 3Rheumatology, Cochin Hospital, Paris, France, 4Rheumatology, Saint-Antoine Hospital, Paris, France

    Background/Purpose:  The evolution of RA and axSpA is characterized by alternated periods of flares and remission. This fluctuating disease activity can be self-assessed by a…
  • Abstract Number: 517 • 2016 ACR/ARHP Annual Meeting

    Association of Rheumatoid Arthritis Disease Activity and Clinical Profile with Chronic Periodontitis

    BEATRIZ RODRIGUEZ-LOZANO1, Jorge Luis Garnier Rodríguez2, Jerián González Febles3, Shashi Dadlani4, Ivan Ferraz-Amaro1, Esmeralda Delgado Frías1, Federico Díaz-González1 and Mariano Sanz Alonso3, 1Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, 2Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, 3Periodontology, Universidad Complutense de Madrid, Madrid, Spain, 4Periodontology, Dental Clinic Garnier, S/C Tenerife, Spain

    Background/Purpose: Recent clinical data show a clear association between periodontitis (P) and RA. However, there is controversy over whether severity of P is associated with…
  • Abstract Number: 757 • 2016 ACR/ARHP Annual Meeting

    Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)

    Richard A. Furie1, Margaret Mitrane2, Enxu Zhao3 and Patrice Becker4, 1Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, 2Manhattan BioPharm Consultants, New York, NY, 3Research and Development; Biometrics, Mallinckrodt Pharmaceuticals, Ellicott City, MD, 4Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD

    Background/Purpose: Multiple outcome measures have been utilized in SLE clinical trials. Consistency of response assessed by different instruments enhances confidence in the efficacy of pharmacologic…
  • Abstract Number: 1220 • 2016 ACR/ARHP Annual Meeting

    Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative

    L Rosenblatt1, K Price1, Y Doleh1, A Szymialis1, M Eaddy2, A Ogbonnaya2, H-C Shih2 and L Lamerato3, 1Bristol-Myers Squibb, Princeton, NJ, 2Xcenda, LLC, Palm Harbor, FL, 3Henry Ford Health System, Detroit, MI

    Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody is a marker used in the diagnosis of RA, and it may be useful in identifying patients who are…
  • « Previous Page
  • 1
  • …
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology